Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Piramal’s Healthcare Vertical Further Expand Commercial ADC Capacity

Published: Monday, August 05, 2013
Last Updated: Monday, August 05, 2013
Bookmark and Share
Piramal | Healthcare was the first contract supplier of ADCs globally.

Piramal’s Healthcare vertical has announced that it is to invest USD 2.5 million at its FDA approved Grangemouth, UK, site to upgrade one of its antibody drug conjugate (ADC) manufacturing suites, from clinical phase to commercial grade, in response to customer demand.

The upgrade will give Piramal two commercial grade ADC suites at the Grangemouth facility, while retaining clinical phase manufacturing capacity in other suites on site.

ADCs are targeted therapies designed to deliver a drug payload to cancer cells while minimizing the adverse effects on normal healthy cell and Piramal | Healthcare was the first contract supplier of ADCs globally.

The batch size offered from the Grangemouth facility ranges from 1-1.5kg and Piramal has capacity for further expansion on site if required.

As part of the investment, the areas supporting the manufacturing suite will also be upgraded to provide new areas for buffer preparation, equipment preparation and antibody freeze / thaw.

Piramal also intends to expand its “Proof of Concept” (POC) offer at Grangemouth, for pharma companies looking to demonstrate antibody and/or toxin suitability for use as an ADC.

“Piramal was a pioneer when it came to the commercial manufacture of ADCs” commented Aidan Walker, President, Formulation Services. “Continued growth in the ADC market and customer demand have led to this latest investment. As part of our POC offer we draw on our vast experience in ADCs to supply model antibodies, the corresponding target cell lines, and non proprietary toxins, to demonstrate suitability of client materials for use in ADC conjugation. We have worked on over 65 ADC candidates and over 30 different ADC drug linkers to date and also have experience with PEGylation, chelating conjugates for radioimmunotherapy and protein toxin conjugates.”

Vijay Shah, Executive Director & Chief Operating Officer of Piramal Enterprises, added, “This investment, supporting an emerging and exciting platform in the field of oncology treatment, aligns completely with our values as an organization. We view ADCs as a strategic area of growth for our Pharma Solutions Business and this investment demonstrates our intention to support our customers with facilities and capacity that can support them into commercial supply”.

The announcement follows the news in October 2012 that Piramal had formed an alliance with Fujifilm Diosynth Biotechnologies through which the two companies offer seamless contract development and manufacture of ADCs.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Inciting an Immune Attack on Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Inflammation Linked to Colon Cancer Metastasis
A new Arizona State University research study led by Biodesign Institute executive director Raymond DuBois has identified for the first time the details of how inflammation triggers colon cancer cells to spread to other organs, or metastasize.
New Strategy for Combating Adenoviruses
Using an animal model they developed, Saint Louis University and Utah State university researchers have identified a strategy that could keep a common group of viruses called adenoviruses from replicating and causing sickness in humans.
Major Advance Toward More Effective, Long-Lasting Flu Vaccine
Collaboration shows vaccine candidate can produce powerful ‘broadly neutralizing antibodies’ in animal models.
Immune System: Help for Killer Cells
A study from the University of Bonn may show the way to more effective vaccines.
Protein Found to Control Inflammatory Response
A new Northwestern Medicine study shows that a protein called POP1 prevents severe inflammation and, potentially, diseases caused by excessive inflammatory responses.
A Leap Forward in Vaccinating Against HIV
A team of scientists has developed an experimental vaccine candidate that successfully stimulates the immune system activity in animal models necessary to stop HIV infection.
MRI Scanners Can Steer Therapeutics to Specific Target Sites
Scientists from the University of Sheffield have discovered MRI scanners, normally used to produce images, can steer cell-based, tumour busting therapies to specific target sites in the body.
Agricultural Intervention Improves HIV Outcomes
A multifaceted farming intervention can reduce food insecurity while improving HIV outcomes in patients in Kenya, according to a randomized, controlled trial led by researchers at UC San Francisco.
Team Finds Early Inflammatory Response Paralyzes T Cells
Findings could have enormous implications for immunotherapy, autoimmune disorders, transplants and other aspects of immunity.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!